UNSPSC 51286906: Olaquindox

This classification denotes an antimalarial agent with the molecular formula C12H13N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G3LAW9U88T, chemically known as 1,4-dihydroxy-n-(2-hydroxyethyl)-3-methyl-1.lambda.~5~,4.lambda.~5~-quinoxaline-2-carboxamide but more generally known as olaquindox, which bears US NIH Compound Identifier 71905. European Medicines Agency schedules Olaquindox in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09427MIG.

The term OLAQUINDOX is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 28, No. 10 1974, List 14). OLAQUINDOX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CC1=C([N+](=O)C2=CC=CC=C2N1[O-])C(=O)NCCO.

UNSPSC 51286906 Olaquindox, a Commodity code, shows minimal alignment with actual state and local procurement activity. The code's nominal scope—olaquindox, a pharmaceutical feed additive for animal production—does not match the recent solicitations tagged under it, which instead focus on naloxone (an opioid overdose reversal medication), pharmacy benefit management, medical and first aid supplies for emergency response, and generic pharmaceuticals for state and local health systems. The mismatch suggests either a cataloging error in the source data or that this code is being used as a catch-all for pharmaceutical-adjacent procurements rather than for its intended commodity. State and local health departments, county community health programs, fire departments, and multistate cooperative purchasing alliances are the issuing bodies appearing in the recent opportunities, but none of these solicitations are actually purchasing olaquindox or related animal-health products.

Geographic activity spans Florida, Texas, Minnesota, and Oregon based on the recent records, but again the connection to the UNSPSC code itself is unclear. Representative opportunities include Seminole County, Florida's IFB for naloxone and drug deactivation systems (posted June 30, 2026, due July 26, 2023), the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (posted April 3, 2026), the City of Tampa's IFB for medical and first aid supplies for its Fire Department Rescue Division with an estimated value of $700,000 (posted March 25, 2026, due March 13, 2026), and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic pharmaceuticals and OTC products (posted January 20, 2026, due March 26, 2026). The code shows no recent procurement activity relevant to olaquindox itself; firms in the animal-health pharmaceutical space should not rely on this code for business-development intelligence.